Comparative Pharmacology
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE IN DEXTROSE versus XYLOCAINE DENTAL WITH EPINEPHRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE IN DEXTROSE versus XYLOCAINE DENTAL WITH EPINEPHRINE.
LABETALOL HYDROCHLORIDE IN DEXTROSE vs XYLOCAINE DENTAL WITH EPINEPHRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at beta-1 adrenergic receptors (cardiac) and selective alpha-1 adrenergic receptors (vascular smooth muscle). Reduces heart rate, myocardial contractility, and peripheral vascular resistance.
Lidocaine blocks voltage-gated sodium channels (Nav1.5, Nav1.7, Nav1.8) in nerve cell membranes, inhibiting sodium influx and preventing depolarization and conduction of nerve impulses. Epinephrine acts as a local vasoconstrictor via alpha-1 adrenergic receptor agonism, reducing systemic absorption and prolonging anesthetic effect.
Adult: Initial 0.5-2 mg/min IV infusion, titrate to response; typical maintenance 2-8 mg/min. Max cumulative dose 300 mg.
Dose range: 1.0–5.0 mL of 2% lidocaine with 1:100,000 epinephrine (20–100 mg lidocaine) injected locally. Maximum dose: 7 mg/kg lidocaine, not to exceed 500 mg total. Epinephrine component limits: 0.2 mg per visit (200 mcg). Repeat doses after 2–3 hours based on response.
None Documented
None Documented
Terminal elimination half-life: 5-8 hours (adults); 8-12 hours (elderly); 2-4 hours (children). Clinical context: half-life may be prolonged in hepatic or renal impairment.
Terminal elimination half-life of lidocaine is approximately 1.5–2 hours in adults, but can be prolonged to 3–5 hours in patients with hepatic impairment or congestive heart failure.
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~50% as metabolites; <5% unchanged in feces.
Lidocaine is primarily metabolized in the liver; less than 10% is excreted unchanged in urine. Metabolites are excreted renally. Biliary/fecal excretion is minimal.
Category A/B
Category A/B
Alpha/Beta-Blocker
Alpha/Beta Agonist